SEC Form 4 · accession 0001209191-15-086746
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen A. Tullman
Director
Period of report
Dec 18, 2015
Accepted (ET)
Dec 22, 2015 · 8:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $28.68 | Dec 18, 2015 | A | 7,095 | A | — | Dec 17, 2025 | Common Stock | 7,095 | 7,095 | D |
Explanation of responses
- F125% of the shares underlying this option will vest on December 18, 2016 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the issuer as of the applicable vesting date.